Drug
RDEA3170 10 mg
RDEA3170 10 mg is a pharmaceutical drug with 7 clinical trials. Historical success rate of 100.0%.
Total Trials
7
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 7 completed trials
Completion Rate
100%(7/7)
Active Trials
0(0%)
Results Posted
57%(4 trials)
Phase Distribution
Ph phase_1
5
71%
Ph phase_2
2
29%
Phase Distribution
5
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution7 total trials
Phase 1Safety & dosage
5(71.4%)
Phase 2Efficacy & side effects
2(28.6%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
7 of 7 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
7
all time
Status Distribution
Completed(7)
Detailed Status
Completed7
Development Timeline
Analytics
Development Status
Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 15 (71.4%)
Phase 22 (28.6%)
Trials by Status
completed7100%
Recent Activity
0 active trials
Showing 5 of 7
completedphase_1
RDEA3170 Tablet and Capsule Bioavailability Study
NCT02448368
completedphase_1
RDEA3170 and Allopurinol Combination Study in Gout Subjects
NCT02279641
completedphase_1
RDEA3170 Bioavailability Study
NCT02336594
completedphase_2
RDEA3170 and Febuxostat Combination Study in Gout Subjects
NCT02246673
completedphase_2
RDEA3170 Monotherapy in Subjects With Gout
NCT01927198
Clinical Trials (7)
Showing 7 of 7 trials
NCT02448368Phase 1
RDEA3170 Tablet and Capsule Bioavailability Study
NCT02279641Phase 1
RDEA3170 and Allopurinol Combination Study in Gout Subjects
NCT02336594Phase 1
RDEA3170 Bioavailability Study
NCT02246673Phase 2
RDEA3170 and Febuxostat Combination Study in Gout Subjects
NCT01927198Phase 2
RDEA3170 Monotherapy in Subjects With Gout
NCT01883167Phase 1
RDEA3170 and Febuxostat Drug Interaction Study
NCT01910506Phase 1
RDEA3170 AME Study
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7